Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea

Table 3 Utility weights according to NYHA subclass obtained from the systematic review

Source	Respondents	Assessment method	Utilities by NYHA subclass				Remarks
Source	Respondents	Assessment method	I	II	III	IV	Remarks
Fox 2007 [21]	Not primary utility study^†	-	0.93	0.78	0.61	0.44	Base case
Kirsch and McGuire 2000 [22]	General population, UK	TTO with EQ5D	0.934	0.782	0.553	0.371	2-year TTO
			0.930	0.765	0.509	0.284	10-year TTO
			0.932	0.774	0.531	0.328	Mean, sensitivity analysis
Lewis 2001 [23]	Advanced CHF (EF < 40) patients, USA	TTO, SG, MLWHF and VAS	0.97	0.80	0.65	0.30	Sensitivity analysis
Calvert 2005 [24]	Patients requiring CRT (NYHA classes III and IV) from the CARE-HF trial, multi-country	EQ-5D and MLWHF	-	-	0.61	0.44	Sensitivity analysis
Göhler 2009 [25]	CHF patients in post AMI from the EPHESUS trial, multi-country	EQ-5D	0.9	0.84	0.74	0.6	Utility in the absence of further comorbidities^‡

AMI, acute myocardial infarction; CARE-HF, Cardiac Resynchronization in Heart Failure; CHF, chronic heart failure; CRT, cardiac resynchronization therapy; EF, ejection fraction; EPHESUS, Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study; EQ-5D, EuroQol-5 dimension; MLWHF, Minnesota Living with Heart Failure questionnaire; TTO, time trade-off.
^†The results from the study of Kirsch and McGuire (2000) [21] were used as utilities for NYHA classes I and II, and the results from the study of Calvert et al. (2005) [23] were used as utilities for NYHA classes III and IV.
^‡This result is not valid because our study population was defined as CHF patients with iron deficiency anemia.

ISSN: 1478-7547